The human Ia region of the major histocompatibility complex (MHC) is composed of a cluster of genes in strong linkage disequilibrium with each other, coding for molecules similar in structure expressed on the surface of B lymphocytes, macrophages, and T cells, especially upon activation. Since the first locus, DR, was recognized in the VII Histocompatibility Workshop, direct evidence has been obtained for at least two more loci, DC and BR, possessing genetic markers defined by specific alloantisera (1) . The products of the DR locus are the predominant species of Ia molecules, accounting for at least 60% of the Ia pool (2). There is no doubt that DR molecules play a role in the mixed lymphocyte reaction (MLR) (3) . Recent studies have shown that proliferation of T cells can be strongly inhibited by pretreatment of either the responder T cells or the stimulating cells with monoclonal antibodies specific for products of the DR locus (4, 5) .
The products of the DC locus constitute a smaller fraction of Ia molecules (2). They have been shown both by microfingerprinting (6) and by two-dimensional gel analysis (7) to differ from DR molecules in both subunits. These substantial structural differences suggested the possibility that DC molecules could have functional properties distinct from those of DR molecules. The availability of a monoclonal antibody (MAb) specifically directed against an allelic DC determinant, DC1 (nomenclature equivalent MB1, MT1, LB12), a DC determinant in strong linkage disequilibrium with DR1,2 and w6 (8) , makes it possible to test this hypothesis.
In this study we have investigated the effect of the anti DC1 MAb on MLR and other in vitro systems. We show here that, unlike anti-DR antibodies, anti-DC1 has no effect on cell proliferation. However, anti-DC 1 affects the generation of effector T cells mediating specific cytolytic activity, whereas no inhibitory effect can be observed on natural killer (NK) and antibody-dependent cytotoxic cell (ADCC) activities.
Materials and Methods
Monoclonal Antibodies. Derivation of the MAb used in the present study has been previously described (6, 9, 10) . The anti-DR PTF29.12 is an IgG2 antibody to a nonpolymorphic determinant of human DR molecules; BT3/4 is an IgG1 antibody directed at a polymorphic determinant of DC molecules present on the DC 1 allele (6). The MAb were used in the form of purified IgG at a final concentration of 50 #g/ml unless otherwise specified.
Cell Cultures. Peripheral blood mononuclear cells (PBMC) were obtained from donors typed for DR and DC1 as previously described (11) . The responding cell population in mixed lymphocyte culture (MLC) consisted either of PBMC or purified T lymphocytes obtained by isolating lymphocytes forming rosettes with neuraminidase-treated sheep erythrocytes (E-rosetting cells) by two sequential centrifugations on Ficoll-Hypaque density gradients. T cells were freed of erythrocytes by treatment with ammonium chloride buffer. The stimulating cell population, consisting of either PBMC or E rosette-depleted cells, was irradiated with 4,500 rad using a Cesium source. Unidirectional MLC were set up by culturing responding cells either in macrowells (10 ~ cells/well) or in round-bottomed microwells (105 cells/well) with equal numbers of irradiated allogeneic cells in RPMI 1640 containing 10% fetal calf serum (FCS) as previously described (11) . Control samples included responding or stimulating cells cultured alone. MAb were added at the onset of the culture, unless otherwise specified, at a dose of 5/~g/well, in the case of microcultures, or at a dose of 50 ~g/well, when MLC were set up in macrowells. Cell proliferation and cytotoxicity were assessed on day 7 as previously described (12) . Briefly, to evaluate cell proliferation, tritiated thymidine ([3H]TdR) was added to triplicate microwell cultures 18 h before harvesting. Cytolytic assays were performed against (a) phytohemagglutinin (PHA)-induced blasts derived from the stimulator cell population, (b) K 562 cell line, and (c) antibody-coated murine L 1210 tumor cells. Varying numbers (37.5 × 104 to 5 × l0 s) of T lymphocytes were incubated in V-bottomed wells of microtiter trays with 5 × 10 a 51Cr-labeled target cells at a final volume of 200/~1, thus ensuring lymphocyte/target cell ratios ranging from 7.5:1 to 100:1. The microplates were centrifuged at 100 g for 7 min. Cytolysis was then assessed by counting the radioactivity of 0.1 ml supernatant for 1 min in a scintillation counter. Specific lysis was calculated according to Cerottini et al. (13) . Pokeweed mitogen (PWM) and tetanus toxoid stimulation were performed as previously described (11) .
Results and Discussion
Unidirectional MLC were set up, to which BT3.4 (anti DC 1) MAb was added at the onset of culture. It should be noted that either the responder or the stimulating cell population was DC 1 positive. As BT3.4 is specific for that allele of the DC locus, this ensured that the antibody could react with the responder or the stimulating cell population, but not with both.
As shown in Table I , in no instance did the presence of the anti-DC 1 Mab inhibit T cell proliferation. Under the same experimental conditions, an anti-DR MAb reduced [3H]TdR uptake to < 10% the control value. Thus, unlike anti-DR antibodies, anti-DC1 does not interfere with T cell proliferation in MLC. Only one experiment is reported for the anti-DR MAb, as it reacts against a nonpolymorphic determinant of DR molecules and hence its effect is independent of the phenotype of the cell. Effector T cells are generated during MLC that are responsible for the lysis of (a) PHA-induced blast cells bearing the stimulating alloantigens, (b) K562 erythroid tumor line (nonspecific killing or NK-like), and (c) antibody-coated target cells (ADCC activity). We have investigated whether the anti-DC 1 MAb had any effect on these various cytolytic activities. As shown in Figs. 1 and 2 , when the effector cells were derived from MLC in which BT3.4 MAb was added from the onset of the culture, a marked difference in terms of specific cytolytic activity (CTL) was observed, depending upon the phenotype of the donors used. In fact, when the responding cells were DC 1 negative and the stimulating cells DC 1 positive (Fig. 1) , no difference could be observed between the specific effector T cells generated in such combination and those obtained from control cultures to which BT3.4 was not added. On the other hand, when the reverse combination was used (responder DC1 positive, stimulator DC 1 negative), those activated T cells generated were virtually devoid of CTL activity. No differences were observed in between the combinations in terms of effector cells capable of killing in ADCC-or in NK-like activity (data not shown). Furthermore, the addition of BT3.4 directly to the cytolytic test could, at this stage, affect neither the specific cytolytic activity of DCl-positive effector T cells generated in MLC nor the killing of DC 1-positive target cells (data not shown).
To check whether the anti-DC1 antibody had any effect on proliferation to a soluble antigen or on B cell differentiation, PBMC from DC 1-positive donors were stimulated in culture with optimal concentrations of PWM or tetanus toxoid in the presence and in the absence of the MAb. Proliferation was evaluated by [aH]TdR uptake, and B cell differentiation was determined by the number of cytoplasmic Ig human Ig antibody and the amount of Ig secreted in the culture fluid. As shown in Table II , the presence of BT3.4 reduced neither proliferation, the number of cIg positive cells, nor the amount of secreted Ig, whereas the anti-DR antibody abolished the response to both PWM and the soluble antigen (data not shown).
The above results show that in in vitro systems the effect of an antibody directed against a product of the DC locus is quite different from that of an antibody directed against a product of the DR locus. Thus, proliferation of T cells, or at least of most of them, is not disturbed by the anti-DC1 antibody, whereas unmasked DC molecules seem to be essential for proliferation and/or differentiation of CTL precursors in MLC. At this stage, however, it is impossible to tell whether these cells are blocked by a negative signal generated by the interaction of the antibody with membrane DC 1 or because masking of the molecule prevents recognition of the allogeneic cell. Nevertheless, it is clear that DC molecules are neither receptors nor target molecules necessary for lysis of the target cells, as shown by the lack of effect of the antibody (6), structurally different from D R molecules, but also that they play distinct functions on the surface of B and T lymphocytes.
S u m m a r y
T h e products of the DC locus have been shown to be structurally different from those of the D R locus. In this p a p e r it is shown that, unlike a n t i -D R antibodies, a monoclonal a n t i b o d y directed against DC 1 does not affect proliferation of T cells in response to alloantigens or soluble antigens or production of Ig in a pokeweed mitogen-stimulated in vitro culture. However, the anti-DC 1 inhibits the generation of effector T cells mediating specific cytolytic activity, whereas no inhibitory effect can be observed on natural killer and a n t i b o d y -d e p e n d e n t cytotoxic cell activities.
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